The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases
Abstract
Background: Assessment of the disease activity in inflammatory bowel disease (IBD) is essential for adequate treatment management and reliable noninvasive biomarkers for verification of mucosal healing are still needed. MicroRNAs (miRNAs) are differentially expressed in IBD and cancer. We aimed to evaluate the potential of circulating and fecal miRNAs as diagnostic biomarkers for IBD. Methods: In this proof-of-principle study we used 2 independent patient cohorts. Testing cohort (n = 96) included serum and fecal samples from controls (n = 35) and IBD patients (n = 61) including 43 patients with Crohn's disease (CD), 18 with ulcerative colitis (UC) with an active disease (n = 38), or in remission (n = 23). Validation cohort included fecal samples from patients with calprotectin/endoscopy-confirmed active disease (n = 30) or in remission (n = 15). Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression. Results: Sera samples from IBD patients showed higher level of miR-16, miR-21, and miR-223, but not miR-155, compared to controls and was higher in CD than in UC patients. Much stronger miRNA expression changes were observed in feces from IBD patients for all studied miRNAs with highest expression of miR-155 and miR-223 in testing and validation cohorts. MiRNA expression correlated with clinical remission, however, only fecal but not circulating miRNAs, correlated with surrogate parameters such as fecal calprotectin or C-reactive protein. Conclusions: Our data provide a novel evidence for differential expression level of fecal miRNAs in IBD. We demonstrate that miRNAs in feces correlate with disease activity and may be considered as potential tool for the further biomarker research in IBD. 10.1093/ibd/izy046_video1izy046.video15794822319001.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have demonstrated that miR-223 is highly expressed in the intestinal tissues, serum, and feces of ulcerative colitis (UC) and inflammatory bowel disease (IBD) patients, suggesting that miR-223 is involved in its regulation and could serve as a biomarker for UC and IBD 108-110.”
From miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation (2021) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Wu, C. W., Ng, S. C., Dong, Y., Tian, L., Ng, S. S. M., Leung, W. W., Law, W. T., Yau, T. O., Chan, F. K. L., Sung, J. J. Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1750 · Cited by 135
Research works printed but not linked: 38
- Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 · DOI · Paper page
- Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to crohn’s disease, Nature, 411, 599, 10.1038/35079107 · DOI · Paper page
- Ogura, 2001, A frameshift mutation in NOD2 associated with susceptibility to crohn’s disease, Nature, 411, 603, 10.1038/35079114 · DOI · Paper page
- Neumann, 2011, New endoscopic approaches in IBD, World J Gastroenterol, 17, 63, 10.3748/wjg.v17.i1.63 · doi:10.3748/wjg.v17.i1.63
- Shergill, 2015, The role of endoscopy in inflammatory bowel disease, Gastrointest Endosc, 81, 1101, 10.1016/j.gie.2014.10.030 · DOI · Paper page
- Soubières, 2016, Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease, World J Gastrointest Pharmacol Ther, 7, 41, 10.4292/wjgpt.v7.i1.41 · DOI
- Konikoff, 2006, Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease, Inflamm Bowel Dis, 12, 524, 10.1097/00054725-200606000-00013 · DOI · Paper page
- Sands, 2015, Biomarkers of inflammation in inflammatory bowel disease, Gastroenterology, 149, 1275, 10.1053/j.gastro.2015.07.003 · DOI · Paper page
- Cappello, 2016, The role of laboratory tests in crohn’s disease, Clin Med Insights Gastroenterol, 9, 51, 10.4137/CGast.S38203 · DOI
- Link, 2010, Fecal microRNAs as novel biomarkers for colon cancer screening, Cancer Epidemiol Biomarkers Prev, 19, 1766, 10.1158/1055-9965.EPI-10-0027 · DOI · Paper page
- Shi, 2013, MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury, PLoS One, 8, e66814, 10.1371/journal.pone.0066814 · DOI · Paper page
- Gracias, 2013, The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling, Nat Immunol, 14, 593, 10.1038/ni.2576 · DOI · Paper page
- Singh, 2014, Mir-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses, Immunology, 143, 478, 10.1111/imm.12328 · DOI
- Link, 2013, MicroRNA in gastrointestinal cancer: a step closer to reality, Adv Clin Chem, 62, 221, 10.1016/B978-0-12-800096-0.00006-8 · DOI
- Wu, 2008, MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha, Gastroenterology, 135, 1624, 10.1053/j.gastro.2008.07.068 · DOI · Paper page
- Takagi, 2010, Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis, J Gastroenterol Hepatol, 25, S129, 10.1111/j.1440-1746.2009.06216.x · DOI · Paper page
- Fasseu, 2010, Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease, PLoS One, 5, e13160, 10.1371/journal.pone.0013160 · DOI · Paper page
- Wu, 2011, Peripheral blood microRNAs distinguish active ulcerative colitis and crohn’s disease, Inflamm Bowel Dis, 17, 241, 10.1002/ibd.21450 · DOI · Paper page
- Archanioti, 2011, Micro-RNAs as regulators and possible diagnostic bio-markers in inflammatory bowel disease, J Crohns Colitis, 5, 520, 10.1016/j.crohns.2011.05.007 · DOI
- Kalla, 2015, MicroRNAs: new players in IBD, Gut, 64, 504, 10.1136/gutjnl-2014-307891 · DOI · Paper page
- Paraskevi, 2012, Circulating microRNA in inflammatory bowel disease, J Crohns Colitis, 6, 900, 10.1016/j.crohns.2012.02.006 · DOI · Paper page
- Shi, 2016, Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer, Gut, 65, 1470, 10.1136/gutjnl-2014-308455 · DOI
- Link, 2012, Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer, Plos One, 7, e42933, 10.1371/journal.pone.0042933 · DOI
- Link, 2014, MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract, Plos One, 9, e100036, 10.1371/journal.pone.0100036 · DOI
- Schulz, 2016, Validation of two calprotectin rapid tests in daily routine, Clin Lab, 62, 1249, 10.7754/Clin.Lab.2015.151101 · doi:10.7754/clin.lab.2015.151101
- Link, 2015, Differential expression of microRNAs in preneoplastic gastric mucosa, Sci Rep, 5, 8270, 10.1038/srep08270 · DOI
- Juzėnas, 2015, Analysis of deregulated microRNAs and their target genes in gastric cancer, PLoS One, 10, 1
- Fisher, 2015, MicroRNA in inflammatory bowel disease: translational research and clinical implication, World J Gastroenterol, 21, 12274, 10.3748/wjg.v21.i43.12274 · DOI
- Iborra, 2013, Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease, Clin Exp Immunol, 173, 250, 10.1111/cei.12104 · DOI
- Zahm, 2014, Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon, J Crohns Colitis, 8, 1108, 10.1016/j.crohns.2014.02.012 · DOI
- Polytarchou, 2015, Assessment of circulating microRNAs for the diagnosis and disease activity evaluation in patients with ulcerative colitis by using the nanostring technology, Inflamm Bowel Dis, 21, 2533, 10.1097/MIB.0000000000000547 · DOI
- Wang, 2016, Circulating microRNA223 is a new biomarker for inflammatory bowel disease, Medicine, 95, e2703, 10.1097/MD.0000000000002703 · DOI · Paper page
- Dalal, 2010, The role of microRNA in inflammatory bowel disease, Gastroenterol Hepatol, 6, 714
- Liu, 2016, The host shapes the gut microbiota via fecal microRNA, Cell Host Microbe, 19, 32, 10.1016/j.chom.2015.12.005 · DOI · Paper page
- Oertli, 2011, MicroRNA-155 is essential for the T cell-mediated control of helicobacter pylori infection and for the induction of chronic gastritis and colitis, J Immunol, 187, 3578, 10.4049/jimmunol.1101772 · DOI
- Johnnidis, 2008, Regulation of progenitor cell proliferation and granulocyte function by microRNA-223, Nature, 451, 1125, 10.1038/nature06607 · DOI · Paper page
- Ben-Shachar, 2016, MicroRNAs expression in the ileal pouch of patients with ulcerative colitis is robustly up-regulated and correlates with disease phenotypes, PLoS One, 11, e0159956, 10.1371/journal.pone.0159956 · doi:10.1371/journal.pone.0159956
- Lin, 2016, Novel microRNA signature to differentiate ulcerative colitis from crohn disease: A genome-wide study using next generation sequencing, MicroRNA, 5, 222, 10.2174/2211536605666161117113031 · DOI
Cited by
Nutrition, IBD and Gut Microbiota: A Review
Mentella, M. C., Scaldaferri, F., Pizzoferrato, M., Gasbarrini, A., & Miggiano, G. A. D. (2020) · Nutrients · doi:10.3390/nu12040944 · Cited by 340
miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation
Jiao, P., Wang, X.-P., Luoreng, Z.-M., Yang, J., Jia, L., Ma, Y., & Wei, D.-W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59876 · Cited by 151
Casado-Bedmar, M., & Viennois, E. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab223 · Cited by 77
Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review
Xu, W.-D., Feng, S.-Y., & Huang, A.-F. (2022) · Inflammation Research · doi:10.1007/s00011-022-01643-6 · Cited by 76
Metadata
- Authors
- Schönauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P., & Link, A.
- Affiliations
- Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-12
- Volume
- 24
- Issue
- 7
- Pages
- 1547-1557
- ISSN
- 1078-0998
- 1536-4844
- Cited by
- 132
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. https://app.cochat.ai/papers/10.1093/ibd/izy046
- The paper
- Schönauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P., & Link, A. (2018). Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izy046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.